“Plainview, NY-based Acupath Laboratories, announced it will meet covid-19 PCR in-lab turnaround time (TAT) of 24 hours or less for all electronically ordering direct bill customers, or the test fee will be waived. This includes employers, school districts, the sports/entertainment industries, and others where testing is required. As testing remains necessary and becomes even more...
“PLAINVIEW, N.Y., March 25, 2021 (GLOBE NEWSWIRE) — Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, today announced it will meet COVID-19 PCR in-lab turnaround time (TAT) of 24-hours or less for all electronically ordering direct bill customers, or the test fee will be waived. This includes employers, school districts,...
ACUPATH LABORATORIES LAUNCHES GUARANTEED 24-HOUR IN-LAB TURNAROUND TIME FOR COVID-19 PCR TEST RESULTS WITHOUT A RUSH FEE Accelerated TAT Comes as New York Lab Marks Processing 500,000 COVID-19 Specimens Since the Start of the Pandemic March 22, 2021, Plainview, N.Y. – Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, today...
INNOVATIVE BLADDER CANCER BIOMARKER DEMONSTRATES COMPELLING CLINICAL UTILITY PLAINVIEW, N.Y., and CAMPBELL, CA, October 27, 2020 – Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, and KDx Diagnostics, Inc., a leading developer of bladder cancer tests, today announced that KDx has selected Acupath to process urine specimens for a formal...
Acupath Laboratories Offers 24-48 Hour Turnaround Time on COVID-19 TESTING Multiplex RT PCR Testing for all 3 coronavirus genes PLAINVIEW, N.Y., August 18, 2020 – Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, now offering COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit. With results...
This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
*electronic orders for direct bill customers only, other terms and conditions may apply.
**insurance availability and copayment/coinsurance requirements are based on current government guidance and is subject to revision if/when plan/payor requirements evolve
The COVID-19 Pandemic is a rapidly evolving situation and guidance is updated frequently. Check your destination’s COVID-19 situation BEFORE traveling. Country, State, local, and territorial governments may have specific travel restrictions or requirements in place. It is ultimately the traveling individuals responsibility to confirm their destinations policy.
© 2024 Acupath Laboratories. All rights reserved
